AIAndré Ilbawi

André Ilbawi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


André Ilbawi has a total of 306 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Conflict and the Cancer Care Continuum in the Middle East: Effects, Economic Burden, and Actionable Solutions

    by Gohar Geghamyan, Sona Karamyan, Maryam Fanian, Samah Mutasim Alfadul, Hojung Choe, Marium Husain, Gevorg Tamamyan, Richard Sullivan, Omar Shamieh, Andre Ilbawi, et al.

    Focusing on the Middle East, this narrative review examines how conflict contributes to delays across the cancer care continuum, including prevention, early detection, diagnosis, treatment, follow-up, survivorship, and palliative care. Mechanisms include the destruction of health facilities, workforce displacement, interrupted supply chains, constrained health budgets, and the diversion of services toward emergency response. These challenges reduce investment in prevention and restrict timely access to therapy, leading to poorer clinical outcomes and increased mortality. Sociocultural barriers, including stigma, misinformation, trauma, and limited public awareness, further delay patient presentation and undermine treatment adherence and continuity of care. This narrative review focuses on peer-reviewed studies and reports published between 2021 and 2026 (with older seminal studies for historical context) to clarify how conflict disrupts cancer care, analyze economic burdens and inequities, and map the relationships between health system fragility and sociocultural barriers. Drawing on this analysis, the review proposes a phased operational framework that tailors strategies—including mobile oncology, tele-oncology, decentralized diagnostics, cross-border referral, and supply chain safeguards—to the security and functional levels of each setting, as well as to governance and financing mechanisms.

  • Open Access

    Systematic Review and Meta-Analyses of Time-Use, Productivity, and Labor Outcomes Among Unpaid Cancer Caregivers

    by Gavin Allman, Lillian Morrell, Filip Meheus, Andre Ilbawi, Isabelle Soerjomataram, Clara MacKay, Frances Reid, Mikis Euripides

    PURPOSE: Unpaid caregivers provide essential support for people with cancer, yet the economic burden of this labor is not well quantified. This study provides pooled estimates of caregiving time and productivity outcomes to better understand the impact of unpaid caregiving on caregivers' economic well-being. METHODS: We systematically searched PubMed and EBSCO databases in June 2025 for peer-reviewed studies reporting primary or secondary data on six prespecified caregiver outcomes related to labor and time-use. Eligible studies focused on adult cancer care and included precision measures. After screening 3,904 records and reviewing 106 full-text articles, 59 studies from 16 countries were included in the meta-analyses. Where required for comparability, outcomes were standardized to a 35-hour work week and 250 workdays per year. RESULTS: Caregivers provided an estimated 45 hours of unpaid care each week (95% CI, 31 to 58). Among employed caregivers, working hours declined by 13% (95% CI, 9 to 18). Caregivers were absent for 5% of working days (95% CI, 4 to 6) and experienced a 24% loss in workplace productivity (95% CI, 20 to 28). In addition, 30% reported reduced job responsibilities (95% CI, 24 to 37) and 1% exited employment (95% CI, –3 to 5). Burdens were greater among caregivers of people with advanced cancer and during palliative care. Women consistently reported greater labor and productivity impacts than men. CONCLUSION: Unpaid caregivers of people with cancer face substantial time- and labor-related burdens that may affect their financial stability and long-term well-being. These findings highlight the need for supportive polices and workplace practices that protect caregiver well-being and economic security throughout the cancer care continuum. They also offer essential evidence to inform policies and interventions that protect caregiver well-being, economic stability, and long-term participation in the workforce.

  • Open Access

    Systematic Review and Meta-Analysis of Labor and Productivity Outcomes Caused by Cancer

    by Gavin Allman, Lillian Morrell, Filip Meheus, Andre Ilbawi, Isabelle Soerjomataram, Clara MacKay, Frances Reid, Mikis Euripides

    PURPOSE: Cancer imposes substantial economic burden through indirect costs associated with labor outcomes and productivity loss. This systematic review and meta-analysis quantifies labor and productivity outcomes among patients with cancer and survivors to inform economic evaluations and policy development. METHODS: We systematically searched PubMed, EconLit, and Web of Science databases in June 2025 using cancer, productivity loss, and labor outcomes terminology. Peer-reviewed studies reporting eight outcomes were included. Following screening of 6,239 abstracts and full-text review of 358 articles, 144 studies from 27 countries met inclusion criteria for meta-analysis. RESULTS: The available evidence skews strongly toward formal employment situations in high-income, Western countries. We estimate a 25% productivity loss due to absenteeism (95% CI, 18 to 32) and a 23% productivity loss due to presenteeism (95% CI, 21 to 26); working hours are reduced by 19% (95% CI, 14 to 24); the return-to-work rate is 47% (95% CI, 39 to 54) with a median time of 239 days for full return; the overall job loss rate is 9% (95% CI, 8 to 11; 35% for advanced cancer; 95% CI, 22 to 48); the unemployment rate is 29% (95% CI, 22 to 36); the long-term disability/pension use is 11% (95% CI, 0 to 22); and the early retirement rate is 14% (95% CI, 8 to 20). For each reported outcome, cancer's productivity costs are observed to be more severe among women than men. CONCLUSION: This represents the largest comprehensive meta-analysis of cancer-related labor outcomes to date. Estimated labor and productivity consequences are in line with previous research, but outcomes varied significantly by gender, cancer stage, geographic region, and time since diagnosis. Subgroup analysis provides nuanced insight into how these factors influence labor and productivity outcomes. These evidence-based estimates provide critical inputs for economic evaluations and support development of policies to maintain professional productivity among patients with cancer and survivors.

  • Open Access

    Childhood Cancer Survival Outcomes in India: A Scoping Review of Three Decades of Survival Data for Policy Insights

    by Shivam Bansal, Rahul Kumar, Poonam Bagai, Sonal Sharma, Swetambri Sharma, Ekta Rahul, Abin Sheref Mohammed, André M. Ilbawi, Carlos Rodriguez-Galindo, Atul Batra, et al.

    PURPOSE: Childhood cancer is an under-recognized public health priority in low- and middle-income countries. India bears a substantial share of the global burden, yet survival outcomes are poorly documented. This scoping review synthesizes survival outcomes across childhood cancers in India, assesses geographic disparities, and benchmarks against international standards to inform national policy and system strengthening. METHODS: We searched PubMed, Scopus, Web of Science, and Embase (January 1994 to December 2023) for studies reporting survival outcomes among childhood cancers (0-18 years) in India. Two reviewers independently screened records, extracted data, and conducted descriptive synthesis by cancer type excluding case reports and registry summaries. Exploratory forest plots were created where ≥3 studies reported comparable end points. The protocol was prospectively registered on Open Science Framework. RESULTS: Of 6,505 records screened, 182 studies (22,886 children) were included. Most were retrospective (78%) and single-center (94%), concentrated in four tertiary hospitals. Exploratory pooled estimates derived from descriptive analyses showed that the 5-year overall (OS) and event-free survival were 67.1% (95% CI, 56.9 to 77.2) and 59.2% (95% CI, 48.0 to 70.3) for ALL and 93.1% (95% CI, 91.7 to 94.4) and 85.3% (95% CI, 81.3 to 89.3) for Hodgkin lymphoma (HL). The pooled median OS for AML and Ewing sarcoma was 25.4 months (95% CI, 16.8 to 33.9) and 21.2 months (95% CI, 14.6 to 27.7), respectively, whereas the 3-year OS for neuroblastoma was 56.9% (95% CI, 45.7 to 68.0). Reporting was inconsistent, with frequent omission of CIs and heterogeneity across regions. CONCLUSION: Childhood cancer survival in India remains variable, with HL nearing global benchmarks, but leukemias and solid tumors show inferior outcomes. Strengthening national cancer registries, research infrastructure, and political commitment is critical for achieving equity in childhood cancer care.


  • Global paid and unpaid productivity losses due to cancer-related mortality

    by Yek-Ching Kong, Jean Niyigaba, Phuong Bich Tran, Jerome Vignat, Freddie Bray, Cindy L Gauvreau, Paul Hanly, Alison Pearce, Marianna de Camargo Cancela, Marta Ortega-Ortega, et al.

    Background: Cancer is among the most important causes of premature deaths globally. We estimated the value of paid and unpaid productivity losses due to premature mortality in 2022 from all cancers worldwide. Methods: Years of productive life lost were derived from cancer mortality data for 36 cancer types among people of working age (15-64 years) in 185 countries for the year 2022. Paid productivity losses were estimated using the human capital approach, while unpaid activities were valued using the opportunity cost approach. Lost productivity was estimated using wages, workforce statistics, and time spent on unpaid activities from various sources. All analyses were performed by sex and age group for each country. Results: In 2022, productivity losses from premature cancer mortality were valued at an estimated US$566 billion, equivalent to 0.6% of the global gross domestic product. Of the total value, 53.9% (US$305 billion) was attributable to paid productivity losses, and 46.1% (US$260 billion) to unpaid productivity losses. Paid productivity losses were generally higher among men, while unpaid productivity losses were greater among women, with variations seen across world regions. The total value of lost productivity was greatest for lung cancer, followed by breast and liver cancers. Per cancer death, testicular cancer, melanoma of the skin, and brain and nervous system cancer generated the highest value of productivity losses. Conclusion: The substantial value of productivity losses from premature cancer mortality highlights its marked societal burden. Continuous investments in global cancer control efforts, including in less common cancers, will yield substantial returns-on-investment to national economies, especially in transitioning countries.


  • Open Access

    Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer

    by Kiu Tay-Teo, Dario Trapani, Manju Sengar, Zeba Aziz, Filip Meheus, André Ilbawi, Elisabeth G.E. de Vries, Lorenzo Moja


  • Top Cited Papers

    Socioeconomic Burden of Ovarian Cancer in 11 Countries

    by Brian Hutchinson, Mikis Euripides, Frances Reid, Gavin Allman, Lily Morrell, Garrison Spencer, Andre Ilbawi, Filip Meheus, Hesham Gaafar, Raffaella Casolino

    PURPOSE: Ovarian cancer remains among the most aggressive tumors with the lowest survival probability. Projections are that ovarian cancer will claim more than 8 million lives between 2022 and 2050 without better prevention or control measures. METHODS: We built an Excel-based instrument that uses a prevalence-based cost-of-illness approach and a societal perspective to estimate the burden of ovarian cancer. The instrument leverages data from editions of the World Ovarian Cancer Coalition's Every Woman Study, contains a micro-costing framework to assess the resources and costs of providing care, and uses data from novel systematic reviews and meta-analyses conducted to estimate the effect of ovarian cancer on patient labor productivity outcomes and the time caregivers devote to caring for people living with the disease. RESULTS: Across 11 countries, we estimated US dollars 70 billion in socioeconomic losses attributable to ovarian cancer. Health expenditures to cover treatment in the first 2 years after diagnosis were 7, 41, and 118 times total health spending per capita in high-, upper-middle-, and low- and lower-middle countries, respectively. Patients spent 3,663 years traveling to or receiving treatment. Women lost labor productivity equivalent to 2.5 million workdays due to ill-health from ovarian cancer, and 9,403 women living with ovarian cancer or survivors were estimated to be missing from the workforce. Caregivers spent 17,112 person-years providing practical support to patients—an average of 33 days per woman living with ovarian cancer. CONCLUSION: This study is the first to quantify the social and economic burden of ovarian cancer in 11 countries and highlights its significant cost and defines actions needed to improve ovarian cancer outcomes.


  • Top Cited Papers

    The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis

    by Richa Shah, Nader Mounir Hanna, Ching Ee Loo, Michael David, Allini Mafra, Hanna Fink, Ethna McFerran, Montse Garcia, Robabeh Ghodssighassemabadi, Suryakanta Acharya, et al.

    The coronavirus disease 2019 pandemic substantially impacted the delivery of cancer services and programs. Here we reviewed and synthesized the global scale and impact of pandemic-related delays and disruptions on cancer services, including diagnosis, diagnostic procedures, screening, treatment and supportive and palliative care. Based on data from 245 articles in 46 countries, we observed declines in the number of cancer screening participation (39.0%), diagnoses (23.0%), diagnostic procedures (24.0%) and treatment (28.0%), ranging from a 15.0% decline for radiotherapy to a 35.0% decline for systemic treatment during the pandemic compared to during the prepandemic period. Medium-human development index (HDI) category countries experienced greater reductions than high- and very-high-HDI countries. Missing data from low-HDI countries emphasize the need for increased investments in cancer surveillance and research in these settings. PROSPERO registration: CRD42022301816


  • Unification of Efforts to Improve Global Access to Cancer Therapeutics: Report From the 2022/2023 Access to Essential Cancer Medicines Stakeholder Summit

    by Edward Briercheck, Doug Pyle, Cary Adams, Rifat Atun, Christopher Booth, Jennifer Dent, Pat Garcia-Gonzalez, Andre Ilbawi, Abdul Rahman Jazieh, David Kerr, et al.

    PURPOSE: There is an urgent need to improve access to cancer therapy globally. Several independent initiatives have been undertaken to improve access to cancer medicines, and additional new initiatives are in development. Improved sharing of experiences and increased collaboration are needed to achieve substantial improvements in global access to essential oncology medicines. METHODS: The inaugural Access to Essential Cancer Medicines Stakeholder Meeting was organized by ASCO and convened at the June 2022 ASCO Annual Meeting in Chicago, IL, with two subsequent meetings, Union for International Cancer Control World Cancer Congress held in Geneva, Switzerland, in October 2022 and at the ASCO Annual Meeting in June of 2023. Invited stakeholders included representatives from cancer institutes, physicians, researchers, professional societies, the pharmaceutical industry, patient advocacy organizations, funders, cancer organizations and foundations, policy makers, and regulatory bodies. The session was moderated by ASCO. Past efforts and current and upcoming initiatives were initially discussed (2022), updates on progress were provided (2023), and broad agreement on resulting action steps was achieved with participants. RESULTS: Summit participants recognized that while much work was ongoing to enhance access to cancer therapeutics globally, communication and synergy across projects and organizations could be enhanced by providing a platform for collaboration and shared expertise. CONCLUSION: The summit resulted in new cross-stakeholder insights and planned collaboration addressing barriers to accessing cancer medications. Specific actions and timelines for implementation and reporting were established.


  • Training cancer workforce to be fit‐for‐purpose and practice in 2024 and beyond

    by André Ilbawi, Raffaella Casolino

    To achieve an oncology workforce that is fit for purpose and sufficient in number, more holistic workforce planning is needed, focusing on educational sector and labor market dynamics. Oncology professionals must be trained and enabled to influence factors affecting their clinical practice including by developing competencies to redesign clinical practice, reduce burnout, and improve productivity and care.